ACUTE MYELOID LEUKEMIA REFRACTORY
Clinical trials for ACUTE MYELOID LEUKEMIA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids battling leukemia that Won't quit
Disease control Recruiting nowThis study is testing a new three-drug combination for children and young adults whose acute myeloid leukemia (AML) has returned or hasn't responded to standard treatments. The goal is to see if adding a drug called venetoclax to two other medications makes chemotherapy more effe…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Apr 03, 2026 19:40 UTC
-
New CAR-T therapy trial targets Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and effectiveness of an experimental treatment called ARD103 for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned after treatment or hasn't responded to standard therapies. ARD103 is a type o…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
First human trial launches for experimental blood cancer treatment
Disease control Recruiting nowThis early-stage study is testing a new drug called APL-4098 to see if it's safe and effective for adults with advanced forms of blood cancer that have returned or stopped responding to other treatments. Researchers will give APL-4098 alone and in combination with two standard ca…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Early trial tests supercharged immune cells to fight tough leukemia
Disease control Recruiting nowThis early-stage study is testing a new combination treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to other therapies. The treatment involves giving patients specially modified immune cells (called CIML-NK cells) from a partially matched…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Experimental nanoparticle drug enters human testing for aggressive leukemia
Disease control Recruiting nowThis is an early-stage study to test the safety of a new drug called Ceramide NanoLiposome (CNL) in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to find a safe dose for future studies. Participants receive th…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Groundbreaking T-Cell therapy trial offers hope for kids with tough leukemia
Disease control Recruiting nowThis early-phase study is testing a new, genetically modified T-cell therapy called SC-DARIC33 in children and young adults (up to age 30) whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe to make a…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for leukemia patients out of options
Disease control Recruiting nowThis study is testing a new drug called AB8939 for people with acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. It's for patients who have already tried…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New immune cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for patients with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The therapy involves modifying a patient's own immune cells to tar…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Massive 4,000-Patient study launched to map survival path for tough blood cancer
Knowledge-focused Recruiting nowThis study aims to collect real-world information on how patients with acute myeloid leukemia (AML) that has returned or not responded to treatment fare across Europe. It will follow 4,000 patients to understand survival rates and which treatments are being used in different hosp…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC